0849 ET - Hims & Hers shares jumped on the news that Novo Nordisk will end its lawsuit against the company and Hims will offer Novo GLP-1s on its platform. That removes a significant legal overhang for Hims, but the partnership could be a near-term hit to its business, say Truist analysts. As part of the deal, Hims will no longer offer compounded GLP-1 drugs, which previously composed a large chunk of its revenue. Still the durability of revenue from branded GLP-1s is much higher, especially given the legal threats Hims' compounded drugs faced. That may make investors willing to assign a higher multiple to Hims, the analysts say. Hims shares climb 51% premarket. (nicholas.miller@wsj.com)

(END) Dow Jones Newswires

March 09, 2026 08:49 ET (12:49 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.